Scholarlink

Background <p>Breast cancer (BC) is a prevalent global malignancy with a high recurrence rate. The effectiveness of predictive, preventive, and personalized treatment strategies is limited by a lack of reliable prognostic biomarkers. Radiotherapy significantly reduces breast cancer recurrence risk and prolongs patients’ lives. However, the role of radiation-related genes in breast cancer remains unclear.</p> Materials and methods <p>Differentially expressed radiation-related genes were identified through analysis of the BRCA gene expression matrix between radiation and non-radiation groups. Multi-omics investigation, including bulk and single-cell RNA sequencing, was conducted to explore these genes in breast cancer. A risk model was developed using random forest, stepAIC, and LASSO Cox regression analyses to predict prognosis, immune cell infiltration, immunotherapy response, and targeted drug sensitivity based on radiation-related gene expression profiles. Functional differences were assessed via Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway and Gene Ontology (GO) enrichment analyses.</p> Results <p>We identified 133 radiation-related differentially expressed genes (DEGs), with 26 hub genes selected via LASSO and random forest models. Single-cell analysis revealed enrichment of radiation-related scores primarily in malignant cells. The radiation-related risk model, validated in the METABRIC dataset and an independent prognostic indicator in the TCGA-BRCA cohort, showed that low-risk patients had higher overall survival rates than high-risk patients. Risk scores correlated with immune infiltration, and low-risk patients exhibited greater immunotherapy response based on immune checkpoint gene expression. Drug sensitivity to gemcitabine, lapatinib, methotrexate, and doxorubicin varied across risk groups.</p> Conclusion <p>To put it briefly, a strong efficient risk model was created to forecast prognosis, TME features, reactions to immunotherapy targeted medications in BRCA. This might lead to new understandings of individualized accurate treatment approaches. To facilitate clinical application, we have developed an R package and Excel-based calculator tool that enables clinicians to easily calculate patient risk scores using the 8-gene signature. These tools, along with detailed usage instructions, are freely available in the supplementary materials and GitHub repository.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Novel radiation-derived gene blueprint stratifying patients with breast cancer

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年9月22日

查看全文
  • Hao Zhang,
  • HongHua Lin,
  • Enyi qiu,
  • Wenqi jin,
  • Shi Dong

摘要

Background

Breast cancer (BC) is a prevalent global malignancy with a high recurrence rate. The effectiveness of predictive, preventive, and personalized treatment strategies is limited by a lack of reliable prognostic biomarkers. Radiotherapy significantly reduces breast cancer recurrence risk and prolongs patients’ lives. However, the role of radiation-related genes in breast cancer remains unclear.

Materials and methods

Differentially expressed radiation-related genes were identified through analysis of the BRCA gene expression matrix between radiation and non-radiation groups. Multi-omics investigation, including bulk and single-cell RNA sequencing, was conducted to explore these genes in breast cancer. A risk model was developed using random forest, stepAIC, and LASSO Cox regression analyses to predict prognosis, immune cell infiltration, immunotherapy response, and targeted drug sensitivity based on radiation-related gene expression profiles. Functional differences were assessed via Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway and Gene Ontology (GO) enrichment analyses.

Results

We identified 133 radiation-related differentially expressed genes (DEGs), with 26 hub genes selected via LASSO and random forest models. Single-cell analysis revealed enrichment of radiation-related scores primarily in malignant cells. The radiation-related risk model, validated in the METABRIC dataset and an independent prognostic indicator in the TCGA-BRCA cohort, showed that low-risk patients had higher overall survival rates than high-risk patients. Risk scores correlated with immune infiltration, and low-risk patients exhibited greater immunotherapy response based on immune checkpoint gene expression. Drug sensitivity to gemcitabine, lapatinib, methotrexate, and doxorubicin varied across risk groups.

Conclusion

To put it briefly, a strong efficient risk model was created to forecast prognosis, TME features, reactions to immunotherapy targeted medications in BRCA. This might lead to new understandings of individualized accurate treatment approaches. To facilitate clinical application, we have developed an R package and Excel-based calculator tool that enables clinicians to easily calculate patient risk scores using the 8-gene signature. These tools, along with detailed usage instructions, are freely available in the supplementary materials and GitHub repository.